Existing users Log In New users Sign up

Key principles of miRNA involvement in human diseases

DISCOVERIES (ISSN 2359-7232), 2014, October-December issue

Giza DE, Vasilescu C, Calin GA. Key principles of miRNA involvement in human diseases. Discoveries 2014, Oct-Dec; 2(4): e34. DOI: 10.15190/d.2014.26

Submitted: December 22, 2014; Revised: December 29, 2014; AcceptedDecember 30, 2014Published: December 31, 2014;

GO BACK to 2014, October-December issue 

Key principles of miRNA involvement in human diseases

(1,2), (3,4) (1,*),

(1) “Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA; 
(2) Department of Hematology, Fundeni Clinical Hospital, Bucharest, Romania; 
(3) Department of Surgery, Fundeni Clinical Hospital, Bucharest, Romania; 
(4) UMF Carol Davila, Bucharest, Romania;

*Correspondence to: George A. Calin, MD, PhD, The University of Texas MD Anderson Cancer Center, Department of Experimental Therapeutics, Unit 1950, 1515 Holcombe Blvd, Houston, TX, 77030-4009, USA, Email: gcalin@mdanderson.org;


Although rapid progress in our understanding of the functions of miRNA has been made by experimentation and computational approach, a considerable effort still has to be done in determining the general principles that govern the miRNA’s mode of action in human diseases. We will further discuss how these principles are being progressively approached by molecular studies, as well as the importance of miRNA in regulating different target genes and functions in specific biological contexts. There is a great demand to understand the principles of context‐specific miRNA target recognition in order to design future experiments and models of normal developmental and disease states.

Access full text of the manuscript here: 


1. Ambros, V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 2003; 113(6): 673-6.

2. Das, J., S. Podder, and T.C. Ghosh, Insights into the miRNA regulations in human disease genes. BMC Genomics 2014; 15: 1010.

3. Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116(2): 281-97.

4. Vasudevan, S., Y. Tong, and J.A. Steitz, Switching from repression to activation: microRNAs can up-regulate translation. Science 2007; 318(5858): 1931-4.

5. Brodersen, P. and O. Voinnet, Revisiting the principles of microRNA target recognition and mode of action. Nat Rev Mol Cell Biol. 2009; 10(2): 141-8.

6. Lytle, J.R., T.A. Yario, and J.A. Steitz, Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR. Proc Natl Acad Sci U S A 2007; 104(23): 9667-72.

7. Place, R.F., et al., MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci U S A 2008; 105(5): 1608-13.

8. Eiring, A.M., et al., miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell 2010; 140(5): 652-65.

9. Kim, D.H. et al., MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc Natl Acad Sci U S A 2008; 105(42): 16230-5.

10. Volinia, S., et al., Reprogramming of miRNA networks in cancer and leukemia. Genome Res. 2010; 20(5): 589-99.

11. Ng, R., et al., A microRNA-21 surge facilitates rapid cyclin D1 translation and cell cycle progression in mouse liver regeneration. J Clin Invest. 2012; 122(3): 1097-108.

12. Rayner, K.J., et al., Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011; 478(7369): 404-7.

13. Zhang, P., et al., MiR-155 is a liposarcoma oncogene that targets casein kinase-1alpha and enhances beta-catenin signaling. Cancer Res. 2012; 72(7): 1751-62.

14. Calin, G.A. and C.M. Croce, MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006; 66(15): 7390-4.

15. Lanford, R.E., et al., Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327(5962): 198-201.

16. Li, Y. and K.V. Kowdley, MicroRNAs in common human diseases. Genomics Proteomics Bioinformatics 2012; 10(5): 246-53.

17. Ha, T.Y., MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease. Immune Netw. 2011; 11(3): 135-54.

18. Calin, G.A. et al., Genetic chaos and antichaos in human cancers. Med Hypotheses 2003; 60(2): 258-62.

19. Gregory, S.M. and B. Damania, KSHV and the toll of innate immune activation. Cell Cycle 2009; 8(20): 3246-7.

20. Calin, G.A., et al., A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005; 353(17): 1793-801.

21. Ling, H., W. Zhang, and G.A. Calin, Principles of microRNA involvement in human cancers. Chin J Cancer 2011; 30(11): 739-48.

22. Calin, G.A., et al., Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004; 101(9): 2999-3004.

23. Chang, T.C., et al., Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007; 26(5): 745-52.

24. He, L., et al., A microRNA polycistron as a potential human oncogene. Nature 2005; 435(7043): 828-33.

25. Wang, D., et al., Human microRNA oncogenes and tumor suppressors show significantly different biological patterns: from functions to targets. PLoS One 2010; 5(9): e13067.

26. Iorio, M.V., et al., MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16): 7065-70.

27. Yanaihara, N., et al., Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006; 9(3): 189-98.

28. Zhan, M.X., et al., [Expression of serum microRNAs (miR-222, miR-181, miR-216) in human hepatocellular carcinoma and its clinical significance]. Zhonghua Yi Xue Za Zhi. 2013; 93(23): 1830-2.

29. Calin, G.A., et al., MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A 2008; 105(13): 5166-71.

30. Costinean, S., et al., Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A 2006; 103(18): 7024-9.

31. Cully, M., et al., Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6(3): 184-92.

32. Mendell, J.T., miRiad roles for the miR-17-92 cluster in development and disease. Cell 2008; 133(2): 217-22.

33. Shen, J., C.B. Ambrosone, and H. Zhao, Novel genetic variants in microRNA genes and familial breast cancer. Int J Cancer 2009; 124(5): 1178-82.

34. Pelletier, C. and J.B. Weidhaas, MicroRNA binding site polymorphisms as biomarkers of cancer risk. Expert Rev Mol Diagn. 2010; 10(6): 817-29.

35. Lu, M., et al., An analysis of human microRNA and disease associations. PLoS One 2008; 3(10): e3420.

36. Garzon, R., et al., Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A 2008; 105(10): 3945-50.

37. Mitchell, P.S., et al., Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008; 105(30): 10513-8.

38. Kauppinen, S., B. Vester, and J. Wengel, Locked nucleic acid (LNA): High affinity targeting of RNA for diagnostics and therapeutics. Drug Discov Today Technol. 2005; 2(3): 287-90.

39. Wang, H., et al., Serum microRNA signatures identified by Solexa sequencing predict sepsis patients' mortality: a prospective observational study. PLoS One 2012; 7(6): e38885.

40. Mishra, P.J., MicroRNAs as promising biomarkers in cancer diagnostics. Biomark Res. 2014; 2: 19.

41. Zhang, H.L., et al., Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2011; 71(3): 326-31.

42. Ling, H., M. Fabbri, and G.A. Calin, MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013; 12(11): 847-65.

43. Kunej, T., et al., The decalog of long non-coding RNA involvement in cancer diagnosis and monitoring. Crit Rev Clin Lab Sci. 2014; 51(6): 344-57.

44. Gupta, R.A., et al., Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010; 464(7291): 1071-6.

45. Ji, P., et al., MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003; 22(39): 8031-41.

46. Rusk, N., AntagoNATs boost gene expression. Nat Methods 2012; 9(5): 437.

47. Ling, H., et al., CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 2013; 23(9): 1446-61.

48. Giza, D.E., C. Vasilescu, and G.A. Calin, MicroRNAs and ceRNAs: therapeutic implications of RNA networks. Expert Opin Biol Ther. 2014; 14(9): 1285-93.

49. Fabian, M.R., N. Sonenberg, and W. Filipowicz, Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 2010; 79: 351-79.

50. Wahlestedt, C., Targeting long non-coding RNA to therapeutically upregulate gene expression. Nat Rev Drug Discov. 2013; 12(6): 433-46.

51. Calin, G.A., et al., Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002; 99(24): 15524-9.

52. Valeri, N., et al., Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A 2010; 107(15): 6982-7.

53. Volinia, S., et al., Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci U S A 2012; 109(8): 3024-9.

54. Jopling, C.L., et al., Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309(5740): 1577-81.

55. Randall, G., et al., Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A 2007; 104(31): 12884-9.

56. Huang, J., et al., Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med. 2007; 13(10): 1241-7.

57. Junker, A., et al., MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 2009; 132(Pt 12): 3342-52.

58. Du, C., et al., MicroRNA miR-326 regulates TH-17 differentiation and is associated with the pathogenesis of multiple sclerosis. Nat Immunol. 2009; 10(12): 1252-9.

59. Lofgren, S.E., et al., Genetic association of miRNA-146a with systemic lupus erythematosus in Europeans through decreased expression of the gene. Genes Immun. 2012; 13(3): 268-74.

60. Trajkovski, M., et al., MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 2011; 474(7353): 649-53.

61. Alisi, A., et al., Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab Invest. 2011; 91(2): 283-93.

62. Martins, M., et al., Convergence of miRNA expression profiling, alpha-synuclein interacton and GWAS in Parkinson's disease. PLoS One 2011; 6(10): e25443.

63. Kim, J., et al., A MicroRNA feedback circuit in midbrain dopamine neurons. Science 2007; 317(5842): 1220-4.

GO BACK to the 2014, October-December issue 

Email Email us at info@discoveriesjournals.org if you have any questions.

News & Events Latest news from Discoveries

  • 2021, July| 2021, Jul-Aug

    Due to the high volume of the submitted articles, both Discoveries and Discoveries Reports are experiencing processing and publication delays in the months of July and August 2021. We will get back to the normal processing and publication times starting in September 2021. Note that our editorial and administrativ work is fully funded by the publishing house at this time and we are striving to KEEP THE NO FEE/NO CHARGE strategy in place as long as possible. 

  • 2021, January| 2021 AWARDS!

    2021 DISCOVERIES AWARDS! Discoveries will offer a $1000 award and several $400 awards in Jan 2022, for the most cited (2021 ISI Citations) and visible (Altmetric Score) articles published in 2018-2021.

  • 2020, November| Follow us on Twitter!

    You can now follow the latest Discoveries news and updates on Twitter! (@DiscoveriesNews) 

  • 2020, August| For Authors!

    Due to a high volume of article submissions, our peer-review process takes more than usual. The pre-screening decision is released in 1-2 days, while the peer-review process lasts between 10 and 20 days.  

  • 2020, April | For Authors!

    WE DO NOT TOLERATE ANY MISCONDUCT! Please be aware that we are testing all received articles with specialized software for PLAGIARISM and WE WILL TAKE MEASURES if your article is already published or in consideration for publication by other journals! This may result in serious professional consequences for the authors. The latest striking case is the following article which is already published and was re-submitted here.  

  • 2020, April | For Authors!

    We are happy to let you know that all articles published in Discoveries are now included in PubMedCentral (PMC). New accepted articles will be included in PMC and PubMed within 1-2 weeks after their publication.

  • 2020, January | For Authors!

    Starting in January 2020, Discoveries will also consider articles submitted by Discoveries' Editorial Board members. However, only a small number of such articles (maximum 4 articles/year) will be considered for publication after the peer-review process, and the authors who are also our editors will be clearly disclosed.  

  • 2019, September | Indexed by PMC

    Discoveries is now indexed by PubMedCentral and Pubmed. The agreement with US National Library of Medicine was signed on September 10, 2019. Our next step is ISI Web of Science indexing. NOTE: previously published articles will be included on PubMed in early 2020.

  • 2019, September | PubMed inclusion!

    We are happy to let you know that Discoveries successfuly passed the last step (Technical Review) required for PubMedCentral and PubMed inclusion!

  • 2019, July | PubMed inclusion News!

    We are happy to receive positive comments from PMC/NLM-NIH regarding Discoveries' last step (Technical Review) required for PubMedCentral and PubMed inclusion. We will let you know once whole indexing process is completed. 

  • 2019| Sharing and Distribution!

    All articles published in Discoveries are Open Access articles distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited and it is not used for commercial purposes.

  • 2018-2019 | For Authors!

    From now on and for at least 1 year, we will only accept articles from authors that are NOT members of Discoveries' Editorial Board. All articles submitted by our editors will be immediately rejected until further notice (one accepted article was already rejected). 

  • 2018 | PubMed inclusion News!

    Discoveries successfully passed the Scientific Quality Review by NLM-NIH for PubMedCentral and PubMed indexing. This is the first and the most important step towards PubMedCentral and PubMed indexing! The second (last) step is the Technical Review.

  • 2016, April | Faster Peer-Review

    Starting on April 13th 2016, all articles selected for a peer-review will receive the post peer-review decision within ~10 days. The initial pre-screening time will remain the same (48h from the submission of the manuscript). This decision will significantly accelerate the publication, with no effect on the quality of the peer-review process.

  • 2016, February | Manuscript submission

    Discoveries is commited to excellence, quality and high editorial standards. We are receiving an increasing number of manuscripts for which the identity of the authors/corresponding author can't be verified. Please NOTE that ALL these articles were and will be immediately REJECTED. Indicating an institutional email address is the easiest way to overcome this problem! Moreover, we do not accept any pressure on our editorial board to accept a manuscript. This results in a prompt rejection of the article.

    Editorial Policies
  • 2016, January | Main Objective

    After reaching all proposed milestones until now (including being indexed by Google Scholar in 2014), Discoveries' next Aim is PubMed indexing of all its articles (already published and upcoming). There will be no charge for the submission or publication of articles before Discoveries is indexed.

  • 2015, August | Discoveries - on PubMed

    We are happy to announce that our first Discoveries articles were included in PMC and PubMed. More articles (submitted by NIH funded authors) are now processed for being included.

    Discoveries articles now on PubMed
  • 2015, April | Special Issue

    DISCOVERIES published the SPECIAL ISSUE entitled "INFLAMMATION BETWEEN DEFENSE AND DISEASE: Impact on Tissue Repair and Chronic Sickness".

    Special Issue on "Inflammation"
  • 2015 | Ischemia Collection

    DISCOVERIES launched a call for papers for a Collection of Articles with focus on "ISCHEMIA". If you are interested to submit a manuscript, please contact us at info@discoveriesjournals.org

  • 2014, September | Special Issue

    DISCOVERIES just publish the SPECIAL ISSUE entitled "CELL SECRETION & MEMBRANE FUSION" in September 2014. Initially scheduled for publication between October 2014-March 2015, this issue was successfully published earlier than scheduled. 

    Special Issue
  • 2014, April | Indexed by Google Scholar

    All our published articles are now indexed by Google Scholar! First citations to Discoveries articles are included! Search for the article's title (recommended) or the authors:

    Google Scholar Search
  • 2014 | DISCOVERIES

    DOIs (Digital Object Identifiers) are now assigned to all our published manuscripts in Discoveries. DOI uniquely identifies an article and is provided by CrossRef.

  • 2013, July | Manuscript Submission

    Submit your manuscript FREE, FAST and EASY ! (in less than 1 minute)! There are NO fees for the manuscript submission or publishing of the accepted manuscripts.
    read more

  • 2013, July | DISCOVERIES

    We are now ACCEPTING MANUSCRIPTS for publishing in DISCOVERIES. We aim publishing a small number of high impact experimental articles & reviews (around 40/year) to maintain a high impact factor. Domains of interest: all areas related to Medicine, Biology and Chemistry ...

    read more
Member Login
Free Registration Click here to sign up
Copyright © 2013 Applied Systems. All Rights Reserved.